CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7/HHLA2 axis, announced today that Chief Executive Officer Ivan Cheung has been named to the 2024 TIME100 Health List.
The inaugural TIME100 Health list recognizes the 100 most influential individuals in health and medicine who have made significant contributions to improving global health outcomes, advancing medical research and driving innovation in healthcare delivery.
“Ivan has demonstrated a relentless commitment to translating scientific breakthroughs into tangible solutions that benefit patients worldwide. The well-deserved recognition by TIME underscores his outstanding contributions to public health and exemplifies his visionary leadership and unwavering dedication to improving the lives of patients,” commented Detlev Biniszkiewicz, PhD, Managing Director at MPM BioImpact and Chairman of NextPoint’s Board of Directors. “Under Ivan’s leadership, NextPoint is advancing a novel class of therapeutics targeting the B7-H7 pathway to improve treatment options for cancer patients that do not respond to PD-1/L1 therapy.”
With over 25 years of experience leading drug development, approvals and launches, Mr. Cheung joined NextPoint as CEO in January 2024 aiming to deliver breakthrough clinical outcomes from a new world of precision immuno-oncology and tumor-targeting therapeutics. He previously served as Eisai’s U.S. CEO, where he guided the launch of the anti-cancer therapy lenvatinib in a range of tumor types. Importantly, Mr. Cheung led the first-ever full U.S. approval for lecanemab, a monoclonal antibody therapeutic to treat the underlying pathophysiology of early-stage Alzheimer’s disease and helped steward the reimbursement access from the Centers for Medicare & Medicaid Services for this class of medicines.
As a member of the TIME100 Health list, Mr. Cheung joins a distinguished group of individuals who are shaping the future of healthcare and driving positive change on a global scale. The full list and related tributes appear in the May 13, 2024 issue of TIME and at time.com/time100health.
About NextPoint Therapeutics
NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients including those who do not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities. To learn more, visit nextpointtx.com.
